Abstract | PURPOSE: METHODS: In this prospective study, 57 eyes of 55 patients with progressive keratoconus, consecutively treated with ultraviolet A (UVA) - riboflavin CXL, were examined with the corneal topographer Pentacam, the biometer IOLMaster and the analyzer of corneal biomechanics Ocular Response Analyzer before and during a 24 months follow-up after CXL. RESULTS: Twenty-four months after CXL, there was a significant improvement in best corrected visual acuity (BCVA) (P<0.01), a significant decrease in corneal thinnest point ( CTP), keratometry readings at the keratoconus apex (K max), and corneal volume (CV) (P<0.01), and a significant increase in axial eye length (AL) (P=0.01). No significant changes in anterior chamber volume (ACV) and depth (ACD), (P=0.8), corneal hysteresis (CH) (P=0.16) and corneal resistance factor (CRF) (P=0.06) were found. However, in the subgroup of patients with decreased K max readings 24 months after treatment, both CH and CRF showed a significant reduction (P<0.01). CONCLUSION: In the first month after the procedure, CXL induces a reduction in corneal volume. During the 24 months follow-up the cornea tends to recover its original volume with a persistence of the CXL efficacy.
|
Authors | Maddalena De Bernardo, Luigi Capasso, Michele Lanza, Antonia Tortori, Stefania Iaccarino, Michela Cennamo, Maria Borrelli, Nicola Rosa |
Journal | Journal of optometry
(J Optom)
2015 Jul-Sep
Vol. 8
Issue 3
Pg. 180-6
ISSN: 1989-1342 [Electronic] Spain |
PMID | 26105541
(Publication Type: Journal Article)
|
Copyright | Copyright © 2013 Spanish General Council of Optometry. Published by Elsevier Espana. All rights reserved. |
Chemical References |
- Cross-Linking Reagents
- Photosensitizing Agents
- Collagen
- Riboflavin
|
Topics |
- Adolescent
- Adult
- Axial Length, Eye
- Child
- Collagen
(metabolism)
- Cornea
(physiology)
- Corneal Topography
- Cross-Linking Reagents
(therapeutic use)
- Female
- Humans
- Keratoconus
(physiopathology, therapy)
- Male
- Photochemotherapy
(methods)
- Photosensitizing Agents
(therapeutic use)
- Prospective Studies
- Riboflavin
(therapeutic use)
- Visual Acuity
- Young Adult
|